全文获取类型
收费全文 | 825篇 |
免费 | 69篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 16篇 |
妇产科学 | 10篇 |
基础医学 | 115篇 |
口腔科学 | 49篇 |
临床医学 | 53篇 |
内科学 | 173篇 |
皮肤病学 | 18篇 |
神经病学 | 64篇 |
特种医学 | 14篇 |
外科学 | 46篇 |
综合类 | 6篇 |
预防医学 | 87篇 |
眼科学 | 6篇 |
药学 | 94篇 |
中国医学 | 5篇 |
肿瘤学 | 134篇 |
出版年
2024年 | 1篇 |
2023年 | 9篇 |
2022年 | 40篇 |
2021年 | 70篇 |
2020年 | 32篇 |
2019年 | 41篇 |
2018年 | 42篇 |
2017年 | 40篇 |
2016年 | 32篇 |
2015年 | 35篇 |
2014年 | 38篇 |
2013年 | 47篇 |
2012年 | 72篇 |
2011年 | 51篇 |
2010年 | 44篇 |
2009年 | 27篇 |
2008年 | 33篇 |
2007年 | 50篇 |
2006年 | 46篇 |
2005年 | 26篇 |
2004年 | 20篇 |
2003年 | 22篇 |
2002年 | 16篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 5篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 3篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1983年 | 5篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1970年 | 3篇 |
1968年 | 2篇 |
1967年 | 2篇 |
1966年 | 1篇 |
排序方式: 共有896条查询结果,搜索用时 15 毫秒
1.
2.
Genetic variants of homocysteine metabolizing enzymes and the risk of coronary artery disease 总被引:2,自引:0,他引:2
Janosíková B Pavlíková M Kocmanová D Vítová A Veselá K Krupková L Kahleová R Krijt J Kraml P Hyánek J Zvárová J Andel M Kozich V 《Molecular genetics and metabolism》2003,79(3):167-175
It is unresolved whether elevated homocysteine in coronary artery disease (CAD) is the cause of arteriosclerosis or its consequence. In contrast, genetic variants of enzymes that metabolize homocysteine cannot be altered by arteriosclerosis. Consequently, their association with CAD would permit to imply causality. We modeled by regression analysis the effect of 11 variants in the methionine cycle upon CAD manifestation in 591 controls and 278 CAD patients. Among the examined variants only the carriership for the c.844ins68 in the cystathionine beta-synthase (CBS) gene was associated with a significantly lowered risk of CAD (OR=0.56; 95% CI=0.35-0.90 in the univariable, and OR=0.41, 95% CI=0.19-0.89 for obese people in the multivariable analysis, respectively). Healthy carriers of the c.844ins68 variant exhibited, compared to the wild type controls, significantly higher postload ratios of blood S-adenosylmethionine to S-adenosylhomocysteine (61.4 vs. 54.9, p=0.001) and of plasma total cysteine to homocysteine (8.6 vs. 7.3, p=0.004). The changes in these metabolites are compatible with an improved methylation status and with enhanced activity of homocysteine transsulfuration. In conclusion, the coincidence of clinical and biochemical effects of a common c.844ins68 CBS variant supports the hypothesis that compounds relating to homocysteine metabolism may play role in the development and/or progression of CAD. 相似文献
3.
Jos J. Mira Martín Blanco Kamila CheikhMoussa Olga Solas Aquilino Alonso Rodrigo Gutierrez Celia Gmez Mercedes Guilabert 《Health expectations》2021,24(2):687
BackgroundIn this COVID‐19 era, we need to rethink the criteria used to measure the results of person‐centred care strategies.ObjectiveTo identify priorities, and criteria that health services can use to pursue actually the goal of achieving person‐centred care.DesignThree‐phase online qualitative study performed during May–July of 2020 using the Delphi technique.Setting and ParticipantsAn online platform was used for a consensus meeting of 114 participants, including health planning experts, health‐care institution managers, clinicians and patients.Main Outcome MeasuresCriteria and indicators for the achievement of person‐centred care.Main ResultsThe first round began with 125 proposals and 11 dimensions. After the second round, 28 ideas reached a high level of consensus among the participants. Ultimately, the workgroup agreed on 20 criteria for goals in the implementation of person‐centred care during the COVID‐19 era and 21 related indicators to measure goal achievement.DiscussionNine dimensions and 28 priorities were identified. These priorities are also in accordance with the quadruple aim approach, which emphasizes the need for care for health‐care professionals, without whom it is impossible to achieve a better quality of care.ConclusionsPerson‐centred care continues to be a key objective. However, new metrics are needed to ensure its continued development during the restoration of public health services beyond the control of COVID‐19.Patient or Public ContributionTwelve professionals and patient representatives participated voluntarily in the construction of the baseline questionnaire and in the selection of the criteria and indicators using an online platform for consensus meetings. 相似文献
4.
5.
6.
Kamila Pires de Carvalho Mariana Tavares Miranda Lima Fernanda Silva Mazzutti Isis Danyelle Dias Custódio Paula Philbert Lajolo Canto Carlos Eduardo Paiva Yara Cristina de Paiva Maia 《Clinical breast cancer》2019,19(1):e208-e219
Purpose
To study the use of functional capacity (FC) level and duration of aromatase inhibitor (AI) therapy with adiposity parameters in women with breast cancer.Patients and Methods
FC was evaluated through the Health Assessment Questionnaire, which was assessed by classification and divided into 3 groups: G1 = mild to moderate difficulty, G2 = moderate to severe disability, and G3 = severe or very severe disability. Body mass, height, and waist circumference (WC) were measured, and body mass index (BMI) was calculated. Bioelectrical impedance analysis was used to calculate body fat (BF) and fat-free mass. The women were divided into 2 time groups (T1 and T2), which were determined by the median months of AI use (T1 ≤ 29.5 and T2 > 29.5 months).Results
Impaired FC and adiposity parameters were significantly positively correlated. In addition, physical exercise was significantly lower in women assessed as G2 and G3 compared to those assessed as G1. The effect of FC on BMI, BF, and WC was also verified, as was the effect of the duration of AI receipt on BMI and BF. Women at T1 had significantly greater functional disability, BMI, and BF values. In addition, although not statistically significant, women in T1 who were assessed as G3 presented higher BMI, WC, and BF values than those in T2.Conclusion
Adiposity above the recommended parameters and impaired FC were associated with the shortest time of receipt of adjuvant endocrine therapy with AI. 相似文献7.
Jastrzebski M Czarnecka D Bacior B Petkow-Dimitrow P Wilczek R Kawecka-Jaszcz K 《Kardiologia polska》2005,63(2):191-5; discussion 196
Two cases of hypertrophic cardiomyopathy with massive hypertrophy and high defibrillation threshold (DFT) are described. A 14-year-old boy, whose single risk factor for sudden death was extreme hypertrophy with maximum interventricular septum (IVS) thickness of 43 mm, survived an episode of ventricular fibrillation. During ICD implantation DFT testing showed energy requirements >30 J and the procedure was aborted. Amiodarone and verapamil treatment was discontinued and treatment with oral sotalol was instituted. After a period of amiodarone washout the procedure was repeated and DFT of 24 J was encountered. An 18-year-old female with massive hypertrophy (IVS thickness=35 mm) and other risk factors for sudden death underwent ICD implantation for primary prevention. During the procedure DFT=20 J and ICD with 30 J maximal output was implanted. An increase in DFT to more than 20 J was encountered during pre-discharge test. Lack of 10 J safety margin warranted ICD system revision and upgrade; during the second procedure DFT was 24 J and ICD with 35 J maximal output was implanted. In summary, in both cases ICDs with 35 J maximal output were successfully implanted. 相似文献
8.
Klaudia Grądzka Kamila Kruczkowska-Tarantowicz Marzenna B. Klimiuk Janusz Kłoczko 《Acta haematologica Polonica》2013,44(3):340-343
Hairy cell leukemia (HCL) is a rare, chronic lymphoproliferative disorder. Currently, purine nucleoside analogs (PNA) constitute the first line treatment of HCL. Cladribine could induce long lasting remission in majority of patients with only a single cycle of therapy. In fact the relapsed patients could be treated successfully with cladribine too. Sometimes we observe the resistance to PNA. Rituximab and chemoimmunotherapy (rituximab plus cladribine) are effective in treatment of refractory HCL.We present a case of a 64-year-old man who was treated with rituximab after second progression of HCL. In March 2011, rituximab was given at a dose of 375 mg/m2 i.v. once a week for eight weeks, with result of achievement of PR. During the last hospitalization in March 2013 the persistence of PR was confirmed. 相似文献
9.